VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy, Targeting IND for Lead Candidate by 2028

VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Thursday, detailing progress during the first half of 2026 and outlining a refined partnering strategy. The company reported that its pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate (ADC) programs, and two non-BiTAC assets available for partnering. VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028.

Company executives cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company’s differentiated BiTAC platform and its potential to secure strategic collaborations. “We are encouraged by the level of engagement from potential pharmaceutical partners and continue to refine both our pipeline and partnering strategy as we advance our next generation of cancer therapies,” the company stated.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL) and is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company’s BiTAC platform is a registered trademark of VERAXA Biotech GmbH. For more details, the full press release is available at https://ibn.fm/xTF5q.

The update comes as the biotechnology sector sees heightened interest in novel immunotherapies. VERAXA’s focus on advancing BiTAC-based T-cell engagers positions it to address unmet needs in solid tumor treatment. The company’s strategy to monetize non-BiTAC assets aims to extend its cash runway and support the costly clinical development process. With the lead candidate VXA-102 targeting IND readiness by early 2028, VERAXA is setting a clear milestone for its most advanced program.

Investors and industry observers will be watching for further partnering announcements and pipeline data. The company’s newsroom, accessible at http://ibn.fm/VRXA, provides ongoing updates on VERAXA’s progress.